RecruitingNCT03923374

Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes

Effects of Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes


Sponsor

Senthil Sadhasivam

Enrollment

600 participants

Start Date

Sep 15, 2018

Study Type

OBSERVATIONAL

Conditions

Summary

The objective of this study is to better understand the comprehensive integration of both clinical and genetic factors that will help to identify mothers who could be at an increased risk of poor response to opioid substitution and infants at risk of significant neonatal abstinence syndrome (NAS).


Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria4

  • Age greater 18 years
  • Currently taking Buprenorphine for Opioid Use Disorder and enrolled in a prenatal opioid maintenance program in the antenatal clinic at IU Health University Hospital.
  • Pregnant with single baby
  • Planned delivery at Methodist, University or Riley Hospital

Exclusion Criteria2

  • Serious maternal medical illness as deemed by study physician or investigator.
  • Known or suspected major fetal/neonatal congenital abnormalities.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSubutex / Buprenorphine

Pregnant Mothers must be taking buprenorphine / subutex for opioid use disorder.

DIAGNOSTIC_TESTFetal & Neonatal MRI

Mothers who consent will be given a fetal MRI and after the baby is born, a neonatal MRI.

DIAGNOSTIC_TESTDNA/Genetic/Pharmacokenetic Blood Draws

Throughout the pregnancy, Mothers will be participating in blood collection throughout the study. At enrollment, we will collect DNA, Genetic and PK blood specimens, then throughout the study, we will be collecting random PK samples.


Locations(1)

UPMC Children's Hospital

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03923374


Related Trials